TEST:

MammaPrint

S2206 trial using neoadj durvalumab with standard chemo in Breast cancer ER+HER2 stage II-III mammaprint ultra high patients. The next big step, using genomic firms in decision taking during the neoadj setting. (@DrMedOnco)

Breast cancer has standardized signatures (PAM50, Mammaprint) so that is plausible. I would love a standard insulin measure. Whether it's output or clearance, exposure to high ins is a risk factor some diseases. Seems metabolites could be standardized too w the right gear for all (@LWellberg)

I think it is unlikely that there were any secretory TNBC cases in the Mammaprint training data. The NTRK angle is interesting. You need a trial of adjuvant larotrectinib for breast like the ADAURA trial for EGFR mutant resected lung ca. (@UnfrznCavemanMD)

Ok another difficult case to crowdsource! 3.5cm pT2N0 secretory carcinoma of the breast, TNBC. Mammaprint basal/high risk. S/p lumpectomy. + LVI. Would you give? #onctwitter #bcsm (@Dr_RShatsky)

#bcsm clinical question. CT2N1 ER 50% PR0% her2 0, invasive ductal. Mammaprint high, Blueprint BASAL. Gets neoadjuvant ddACT. Path has ypT1b residual. Do u give adjuvant abemaciclib? ()

MammaPrint and BluePrint tests provide accurate results for thousands of women. Regardless of age.* #SGBCC2023 #breastcancer *MammaPrint® FFPE is CE-marked, and FDA-cleared for 18 years or older. ()

NCCN Adds MammaPrint Gene Expression Assay to Breast Cancer Guidelines https://t.co/QYDm41PyyM via @onclive #BCSM Women in ultralow risk category can avoid collateral damage from treatment. Big step forward. Congrats @DrLauraEsserman, @LVVPrint ()

Glad to see the expansion of tools for profiling of breast cancer. MammaPrint offers ultra low-risk threshold which can make the difference in doing less safely. Coming soon: response predictive subtypes (testing in ISPY) to further tailor Tx in the high-risk setting @LVVPrint ()

@Agendia is delighted to attend the post SABCS Belgium tonight and tomorrow #mammaprint #blueprint #breastcancer ()

#SABCS22 MammaPrint in the IDEAL trial: may predict benefit from extended endocrine therapy (10 vs 7.5 yrs) in the genomic-low-risk but not in the high-risk or ultra-low-risk. Unclear if clinical risk plays a role. How do we reconcile this data with prior data from BCI? ()

MammaPrint & extended endocrine therapy benefit in IDEAL trial *MP high: no significant benefit *MP low: derive benefit from extended ET *MP ultralow: risk cannot be evaluated in IDEAL Consistent with prior NSABP-B42 analysis. Laura van't Veer @UCSFCancer #SABCS22 ()

#sabcs2022 MammaPrint & extended endocrine therapy benefit in IDEAL trial *MP low (not ultralow nor high):derive benefit from extended ET @gary_lyman @OncoAlert ()

Tomorrow in San Antonio #mammaprint #blueprint #SABCS2022 ()

Join Agendia at #EBCC13 in Barcelona! Please stop by booth #B3 to discuss the latest data on #MammaPrint and #BluePrint, our comprehensive genomic #breastcancer tests. ()

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer https://t.co/srq627E7HR Both the original and the update of the Raster trial are so juicy! ()

Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study. https://t.co/tqovS3Hgai @NienkedeGlas @WilliamDale_MD @rochgerionc @myCARG #GeriOnc ()

Drs. @VeredStearns & Raquel Nunes discuss the role of Oncotype DX and MammaPrint, two validated gene signatures that are commonly used for premenopausal women with HR-positive, HER2-negative #BreastCancer. https://t.co/8j5kUVKqun #ASCODailyNews #bcsm ()

Otto Metzger giving a comprehensive clinical analysis of #Lobular at #ILCSymposium 10% ILC are High Genomic Risk by Mammaprint @Otto_DFCI @LobularIreland @elbcc @sflomos @CANCERPREV1 @IrishCancerSoc @CancerInstIRE @damirvareslija @CancerCentreIre @NiTriona ()

I-SPY2: pCR by molecular subtype for HR+/HER2- breast cancer. Higher pCR rates in Mammaprint High2, Blueprint Basal, and RPS immune+ signature. Future randomization planned based on RPS subtype. @laura_huppert @hoperugo of @UCSFCancer #ASCO22 #bcsm ()

#CedarsSinaiCancer at #ASCO22. Dr. Alice Chung will be presenting “Identification of transcriptional changes with #MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant #chemotherapy.” @ASCO @CedarsSinaiMed @CSCancerCare @AGiulianoMD #Breastcancer ()

So ISPY2 enrolls all mammaprint high risk who have tumors >2.5cm so not just TNBC. We have had de-escalation longer than Keynote 522 data was standard of care so most have not gotten adjuvant IO. ISPY2 trial ends at surgery so up to providers what they want to do adjuvantly #bcsm ()

#bcsm Time for another controversial treatment poll! Young patient (under35), Luminal B tumor (by Oncotype or Mammaprint), pT2N0 (4cm). ()

#BreastCancer #Monterrey #Oncology #ClinicalCase #ClinicalScenario #MammaPrint #Cancer #Genomic #Adjuvant #Chemotherapy @drdonsdizon @rodbox44 @BrizioMoreno @Dr_Zamudio @AChargy @DrHectorDiaz @DrDAGP_OM @Dra_CVillarreal @anelcabrera @mivan_eduardo @hectordelamora @AlethiaAlvarez ()

#CedarsSinaiCancer at #SABCS21. Dr. Alice Chung and Dr. Armando Giuliano @AGiulianoMD are co-authors on “#Mammaprint and Blueprint are prognostic of outcome following neoadjuvant #Chemotherapy” presented at Poster Session 4. #CedarsSinai @SABCSSanAntonio (@CSCancerCare)

Great Debate #SABCS21 -- Chemo vs OS (Loibl): Current genomic markers (eg Oncotype and MammaPrint) do not fully capture prognostic risks appropriately for younger #bcsm pts (developed mainly in postmeno). We need to also look at longitudinal ER, PR, Ki67, +/-TILs @gary_lyman (@NicoleKuderer)

Results: Mammaprint risk category significantly associated with survival outcomes but failed to predict benefit of chemo for patients w/ #lobular #breastcancer @LobularBCA @LobularIreland @LobularBCUK @amymccart @Otto_DFCI @oesterreichs #bcsm @OncoAlert https://t.co/IBw1FsGCc2 (@LPseattle)

#agendia #BreastCancerAwarenessMonth #mammaprint (@julieeberlelife)

Utility Of The 70-gene MammaPrint Assay For Prediction Of Benefit From ELT Adam Brufsky, MD @breastoncdoc @UPMCHillmanCC @MageeWomens #ASCO21 #BreastCancer #Cancer #Research https://t.co/IEVjzAb934 (@oncologytube)

3rd & final talk for #CAHON highlights from #ASCO21: Dr. #TianhongLi @ucdavis gives breast cancer updates - covering OlympiA adjuvant PARP, ICIs in neoadjuvant tx, & biomarkers w/ Mammaprint update. A lovely wrap-up to our conference tonight. Thanks to all of our speakers! (@TiansterZhang)

Neither MammaPrint or BCI were predictive/prognostic in B-42 study. See my summary attached. Very confusing data though... #bcsm (@paspears88)

It used Mammaprint, a 70 gene signature, to assign breast cancer risk. #ASCO21 (@drdonsdizon)

#ASCO21 Locallyadvanced #BreastCancer 😃Adjuvant PARPi ☹️Platinum for pts with residual TNBC post neo ☹️BCI-H/I prediction of extended ET 🙂Mammaprint prediction of extended ET 😕Neo Durvalumab 🙂neo weekly paclitaxel+TP 🙂Neo talazoparib in early gBRCAm HER2− #BCSM @OncoAlert (@jesusanampa)

Mammaprint to assess benefit -extended adjuvant endocrine Rx @NSABPFoundation B 42 trial - Mammaprint Low may be useful in identifying patients who may benefit from extended adjuvant. But I don't think it will change our practice overnight. #BCSM #OncoAlert @OncoAlert #ASCO2021 (@jamecancerdoc)

Mammaprint ability to predict benefit from Ext letrozole in B-42: 📍benefit for Ext therapy in MP-L, not MP-H 📍benefit appears to be driven by the low group (not ultralow tumors) which represents about 59% tumors @OncoAlert #bcsm #ASCO21 (@ErikaHamilton9)

The findings re: #Mammaprint seem to be very big game changers for me but I await guidance from our new leader in #breastoncology, @DrSGraff #bcsm #ASCO21 @RIHospital @BrownUCancer (@drdonsdizon)

#ASCO21. In early #bcsm #MINDACT trial (N~6.7K), at ~8y f/u, the 15% of pts classified as ultra-low risk by Mammaprint 70-gene had few distant mets/deaths w/ endocrine tx alone or no systemic tx, regardless of clin risk. We can prob give fewer pts endo tx. #PatientExpererience (@tmprowell)

Very important news #bcsm #MINDACT trial Abstr 500 Sending the 70-gene signature Mammaprint panel for people with HR+HER2- breast cancer could find those with ultralow risk, in whom NO adjuvant therapy looks like an entirely reasonable option. (@drdonsdizon)

many ER+ tumors do not necessarily respond well to chemo, so genomic tests on the cancer (such as oncotype, mammaprint or others) may be performed to determine if chemo even has a benefit #bcsm 2/ (@DrAttai)

ICYMI - the recorded ⁦@ASBrS⁩ Breakfast Symposia April 30th supported by ⁦@Agendia⁩ featuring ⁦@WhitworthMD⁩ & ⁦@william_audehmd⁩ discussing #MammaPrint + #BluePrint #bcsm https://t.co/bkpCcTs0ky (@KBHock90)

Join the @Agendia team for an @ASBrS virtual breakfast symposium this Fri 4/30 at 9:00a est @WhitworthMD @william_audehmd A Case-Based Discussion of Integrating MammaPrint and BluePrint into Treatment Planning for Patients with Early Stage Breast Cancer https://t.co/GDPRyRt6AE (@KBHock90)

listening to the great @DrHBurstein at 2021 St. Gallen Consensus Breast Cancer Conference Do all pts with early-stage Luminal B, or RS >25, or MammaPrint-high need chemo? I think we missed a unique opportunity to better test this in randomized trials https://t.co/Obz1x9qpCH (@prat_aleix)

Are you using #genomictesting at the right time, for the right patients? #bcsm #mammaprint @Agendia @WhitworthMD #SABCS20 (@KBHock90)